Appendix 4D - Half Year Accounts - 31 December 2018
Filed with ASX · · 23 pages · English
1. Company details Name of entity: ABN: Reporting period: Previous period: 2. Results for announcement to the market Dividends There were no dividends paid, recommended or declared during the current financial period. The profit for the Consolidated Entity after providing for income tax amounted to $891,656 (31 December 2017: loss of $994,326). During the period, the Group had total revenue of $21
Story so far
Earlier from Patrys
- Appendix 4C - Quarterly - 31 December 2018
- PAT-DX1 Suppresses Breast Cancer Brain Metastases
- Appendix 4C - Quarterly - 30 September 2018
- Settlement of Manufacturing Claims
- PAT-DX1 Clinical Target Indications Confirmed
Later from Patrys
- Market Update
- Appendix 4C - Quarterly - 31 March 2019
- PAT-DX1 Reduces Brain Metastases, Enhances Radiation Therapy
- Europe grants patent for Deoxymab 3E10
- PAT-DX1 significantly improves survival in aggressive GBM
Follow Patrys into a list and get an email when it puts out news.
Follow Patrys